Long-Term Survival, Toxicity Profile, and role of F-18 FDG PET/CT scan in Patients with Progressive Neuroendocrine Tumors Following Peptide Receptor Radionuclide Therapy with High Activity In-111 Pentetreotide
<p><b>Aim</b>: To study the long term benefits, toxicity and survival rate in patients with neuroendocrine tumors receiving multiple cycles of high activity In-111 Pentetreotide therapy. Moreover, our secondary aim was to evaluate the value of F-18 FDG PET-CT scan as prognostic ind...
Main Author: | Ebrahim S. Delpassand, Amin Samarghandi, Jennifer Sims Mourtada, Sara Zamanian, Gregory D. Espenan, Roozbeh Sharif, Shawn MacKenzie, Kambiz Kosari, Omar Barakat, Shagufta Naqvi, John E. Seng, Lowell Anthony |
---|---|
Format: | Article |
Language: | English |
Published: |
Ivyspring International Publisher
2012-01-01
|
Series: | Theranostics |
Online Access: | http://www.thno.org/v02p0472.htm |
Similar Items
-
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide.
by: Kwekkeboom, D, et al.
Published: (2009) -
Carcinoid tumours presenting as breast cancer: the utility of radionuclide imaging with 123I-MIBG and 111In-DTPA pentetreotide.
by: Kaltsas, G, et al.
Published: (1998) -
Production and Quality Control of Indium-111 Pentetreotide Radiopharmaceutical in Iran
by: S. Y Fazaeli Hoseini Nezhad, et al.
Published: (2017-08-01) -
Automatic and manual image fusion of <sup>111</sup> In-pentetreotide SPECT and diagnostic CT in neuroendocrine tumor imaging - An evaluation
by: Hedlund Elisabeth, et al.
Published: (2010-01-01) -
111 In-pentetreotide SPECT CT Value in Follow-up of Patients with Neuro-Endocrine Tumors
by: Badriya Al-Suqri
Published: (2014-09-01)